BDNF Val66Met, A beta amyloid, and cognitive decline in preclinical Alzheimer's disease

Lim, Yen Ying, Villemagne, Victor L., Laws, Simon M., Ames, David, Pietrzak, Robert H., Ellis, Kathryn A., Harrington, Karra D., Bourgeat, Pierrick, Salvado, Olivier, Darby, David, Snyder, Peter J., Bush, Ashley I., Martins, Ralph N., Masters, Colin L., Rowe, Christopher C., Nathan, Pradeep J. and Maruff, Paul (2013) BDNF Val66Met, A beta amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 34 11: 2457-2464. doi:10.1016/j.neurobiolaging.2013.05.006


Author Lim, Yen Ying
Villemagne, Victor L.
Laws, Simon M.
Ames, David
Pietrzak, Robert H.
Ellis, Kathryn A.
Harrington, Karra D.
Bourgeat, Pierrick
Salvado, Olivier
Darby, David
Snyder, Peter J.
Bush, Ashley I.
Martins, Ralph N.
Masters, Colin L.
Rowe, Christopher C.
Nathan, Pradeep J.
Maruff, Paul
Title BDNF Val66Met, A beta amyloid, and cognitive decline in preclinical Alzheimer's disease
Journal name Neurobiology of Aging   Check publisher's open access policy
ISSN 0197-4580
1558-1497
Publication date 2013-11-01
Year available 2013
Sub-type Article (original research)
DOI 10.1016/j.neurobiolaging.2013.05.006
Open Access Status
Volume 34
Issue 11
Start page 2457
End page 2464
Total pages 8
Place of publication Philadelphia, United States
Publisher Elsevier
Language eng
Formatted abstract
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has previously been implicated in Alzheimer's disease (AD)–related cognitive impairment. We aimed to determine the relationship between BDNF Val66Met and beta-amyloid (Aβ) on cognitive decline, hippocampal atrophy, and Aβ accumulation over 36 months in 165 healthy adults enrolled in the Australian Imaging, Biomarkers and Lifestyle study. In healthy adults with high Aβ, Met carriers showed significant and moderate-to-large declines in episodic memory, executive function, and language, and greater hippocampal atrophy over 36 months, compared with Val/Val homozygotes. BDNF Val66Met was not found to be related to rates of change in cognition or hippocampal volume in healthy adults with low Aβ. BDNF Val66Met did not relate to the amount of Aβ or to the rate of Aβ accumulation in either group. High Aβ levels coupled with Met carriage may be useful prognostic markers of accelerated cognitive decline and hippocampal degeneration in individuals in the preclinical stage of AD.
Keyword BDNF Val66Met
beta-Amyloid
Cognitive decline
Hippocampal atrophy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 31 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 39 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 07 Dec 2013, 04:41:13 EST by System User on behalf of School of Medicine